Name

Altos Labs

Legal name

Altos Labs, Inc.

Website

https://altoslabs.com

Company type

Private

Founded year

2022

Operating status

Operating

Headcount range

251–500 employees

Ownership category

akta.pro rank

Product category

Biotechnology Research

NAICS

Analytical Laboratory Instrument Manufacturing (334516), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Computer Systems Design and Related Services (5415)

SIC

Laboratory Analytical Instruments (3826), Services-Computer Integrated Systems Design (7373), Electronic Computers (3571)

akta.pro primary industry

AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE)

akta.pro secondary industries

Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization) (HLAAAIAC), Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB), Cellomics & High-Content Screening (HCS) Services (HLAGANAD), AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO), Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development) (HLAAAIAD)

Keywords

• Cellular rejuvenation research
• Epigenetic reprogramming therapeutics
• Biotechnology drug discovery
• Aging disease reversal
• Computational biology platform

Headquarters

HQ city

San Francisco

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales

Revenue model

1. Pre-revenue R&D biotech: Altos Labs is a private, pre-revenue biotechnology company focused on cellular rejuvenation research. Revenue generation is not yet applicable as the company is still in the discovery, preclinical, and translational research phase, building medicines that will eventually be commercialized through drug development pipelines or partnerships.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels6 records

Core offering

Altos Labs is a pre-revenue biotechnology company focused on cellular rejuvenation programming to restore cell health and resilience and reverse disease. Its core offering is a research and drug discovery platform built on partial epigenetic reprogramming using Yamanaka factors (Oct4, Sox2, Klf4, c-Myc), operationalized through three Institutes of Science, an Institute of Medicine, and an Institute of Computation. Future commercialization is expected through biopharma partnerships, licensing, and internal drug development pipelines.

Product overview

Altos Labs is a single platform company — not a multi-product SaaS suite — built around one core therapeutic platform: cellular rejuvenation programming to restore cell health and resilience and reverse disease, injury, and the disabilities that occur throughout life. The platform is organized as a hub-and-spoke architecture comprising three Institutes of Science (the Bay Area Institute of Science in Redwood City, CA; the San Diego Institute of Science; and the Cambridge Institute of Science in the UK) that pursue deep biological questions on rejuvenation and reprogramming, a translational Institute of Medicine (IoM) led by Dolo Diaz and Joan Mannick that converts discoveries into medicines, and an Institute of Computation (IoC) led by Hana El-Samad that builds multi-scale generative AI models to decode cell health. Together, the Institute of Computation provides AI/ML infrastructure and models, the Institutes of Science generate biological hypotheses and pre-clinical data, and the Institute of Medicine develops transformative therapeutics — all feeding the cellular rejuvenation programming core platform. Founding science is rooted in Shinya Yamanaka's induced pluripotent stem cell research and Juan Carlos Izpisua Belmonte's partial reprogramming breakthroughs.

Differentiator

Problem solved

Functional benefit

Products and services

• Cellular Rejuvenation Programming Platform Foundational scientific and therapeutic platform focused on restoring cell health and resilience through partial cellular reprogramming using Yamanaka factors (Oct4, Sox2, Klf4, c-Myc). Resets cells to a state more resilient to stressors while retaining cell identity and youthful functions. Forms the core of Altos Labs' pipeline for future therapeutic development.
• Bay Area Institute of Science One of three Altos Labs Institutes of Science, located in Redwood City, CA (San Francisco Bay Area). Directed by Jodi Nunnari, PhD, with principal investigators working on mitochondrial biology, microproteome (Jin Chen), cognitive dysfunction (Susanna Rosi), integrated stress response (Mauro Costa-Mattioli), and homeostasis (Adam Frost).
• San Diego Institute of Science Altos Labs' San Diego-based Institute of Science conducting research on genome technologies, bioengineering, single-cell sequencing, stem cell aging, and nuclear proteostasis. Principal investigators include Kun Zhang (genomics and bioengineering) and Pura Muñoz-Cánoves (stem cell aging), with Zachary Levine focusing on promiscuous protein assemblies.
• Cambridge Institute of Science (UK) Altos Labs' United Kingdom Institute of Science located in Cambridge, directed by Wolf Reik, MD. Research focuses on epigenetic reprogramming in development and aging, nuclear envelope dysfunction (Delphine Larrieu), cellular senescence and reprogramming (Manuel Serrano), neurodegeneration and the Unfolded Protein Response (Giovanna Mallucci), adult CNS stem cell aging (Robin Franklin), and histone/DNA methylation changes (Ken Raj).
• Institute of Medicine (IoM) Altos Labs' translational institute that captures knowledge about cell health and programming to develop transformative medicines. Led by Dolo Diaz, PhD (Global Head and SVP of Drug Discovery and Development Sciences), Joan Mannick, MD (SVP, CMO and Head of Product Development), and Sharon Wang, PhD (Global Head and SVP of Technical Operations). Translates breakthrough science into breakthrough medicines.
• Institute of Computation (IoC) Altos Labs' newly formed scientific institute focused on building computational models that decode the language of biological resilience at the cell, organ, and organism levels. Directed by Hana El-Samad, PhD. Founding Principal Investigators Morgan Levine (VP, Computation, formerly Yale) and Simone Bianco (VP, Computation, formerly IBM Almaden Research Center); Bikash Sabata serves as VP of Software and Platforms. Leverages AI/ML to program cells to a state of resilience.

Quantifiable outcome

• Up to 30% extension of mouse lifespan through partial cellular reprogramming in preclinical studies
• +2 more outcomes

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability8 records

Feature6 records

Partnerships

Five partnerships are on record, tiered minor and core.

• Cyclana BiominorStrategic or Co-development Partner · 30 October 2025British biotech Cyclana Bio secured $6.6 million in pre-seed funding and was founded by former Altos Labs scientists. It develops therapies for chronic inflammation-driven diseases starting with endometriosis, creating tissue models to improve drug discovery.
• IBM Almaden Research CenterminorStrategic or Co-development PartnerSimone Bianco, now VP of Computation at Altos Labs, previously was a research staff member and manager of Functional Genomics and Cellular Engineering at IBM Almaden Research Center, providing talent and expertise transfer into Altos's Institute of Computation.
• UCSF (University of California, San Francisco)coreStrategic or Co-development PartnerHana El-Samad, SVP and Director of Institute of Computation, was previously the Kuo Family Endowed Professor at UCSF. Multiple principal investigators (Adam Frost, Susanna Rosi) were recruited from UCSF, forming a deep academic talent pipeline.
• Yale University School of MedicinecoreStrategic or Co-development PartnerMorgan Levine, VP of Computation, was previously a ladder-rank professor at Yale School of Medicine. Zachary Levine, PI at San Diego Institute, continues as adjunct faculty at Yale. Yale School of Medicine is a source of biological clocks and aging expertise.
• Salk Institute for Biological StudiescoreStrategic or Co-development PartnerJuan Carlos Izpisua Belmonte, Altos's Founding Scientist and SVP, was previously the Roger Guillemin Chair and Professor at the Salk Institute. Travis Berggren, VP of Scientific Operations, joined from the Salk Institute where he was Executive Director of Research Operations.

Scale indicators7 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• Calico Labs: Alphabet-backed life sciences company focused on aging and longevity, with an academic-style research model and deep funding. Directly comparable to Altos in mission, scientific posture, and capital intensity, though Calico's therapeutic programs are less publicly disclosed.
• Life Biosciences: Cellular rejuvenation biotech pursuing partial reprogramming and related gene therapy approaches to age-related disease. Highly comparable to Altos on platform approach and target indications, though smaller in capital base and institute footprint.
• NewLimit: Epigenetic reprogramming biotech focused on restoring youthful function in aged cells, also backed by tech-billionaire capital (including Jeff Bezos). Closely comparable to Altos on core platform science (Yamanaka factors) and longevity focus.
• Turn Biotechnologies: Clinical-stage epigenetic reprogramming company developing mRNA-based OSKM delivery to restore youthful cellular function. Comparable to Altos on core reprogramming science, with a more clinical-stage asset profile.
• Unity Biotechnology: Clinical-stage biotech developing senolytic therapies to clear senescent cells for age-related disease. Comparable to Altos on aging-therapeutics market, with differentiated mechanism (senolytics vs. partial reprogramming).

Broad incumbents

• Insilico Medicine: AI-driven drug discovery company with a longevity-focused pipeline and proprietary Pharma.AI platform. Comparable to Altos on the AI/ML-meets-aging intersection, though Insilico is broader and more clinically advanced across multiple therapeutic areas.
• Recursion Pharmaceuticals: Publicly traded AI-driven biotech combining high-throughput biology with ML for drug discovery. Comparable to Altos on the integration of large-scale data and AI/ML in pharmaceutical R&D, though Recursion is platform-agnostic rather than aging-focused.

Others

• Hevolution Foundation: Saudi-backed non-profit foundation funding geroscience and longevity research globally. Comparable to Altos as a funder in the longevity space and a potential capital or partnership counterparty rather than a direct therapeutic competitor.

Emerging players

• Denali Therapeutics: Biotech developing therapeutics for neurodegeneration with strong talent ties to the Bay Area biotech ecosystem (Altos's Dolo Diaz joined from Denali). Comparable to Altos on neurodegenerative disease focus and translational model, though Denali is more clinical-stage and broader in scope.
• Loyal for Dogs: Veterinary longevity biotech developing drugs to extend healthy lifespan in dogs as a stepping stone to human therapies. Comparable to Altos on aging therapeutics mission, with a differentiated companion-animal go-to-market that de-risks translation.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/altos_labs
• LinkedInlinkedin.com/company/altoslabs

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles19 records

Funding overview

Funding rounds1 record

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Altos Labs